-Demonstrates How Clinically Proven Celadrin(R) Achieves Its Results
SAN DIEGO, March 19 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today that Director of Research and Development, Dr. Robert Hesslink, presented basic research outlining the cellular pathway instrumental in the efficacy of Celadrin(R). Dr. Hesslink outlined the pathway before an audience of scientists and industry leaders at the Nutrigenomics 2008 meeting in Paris, France. The meeting was sponsored by the International Society of Antioxidant in Nutrition and Health and held at the prestigious Universite Paris V, Faculte de Medecine Paris Descartes.
The clinical efficacy of Celadrin(R) has been published in such esteemed journals as the Journal of Rheumatology and the Journal of Strength Conditioning and Research. It has been shown that Celadrin(R) reduces joint and muscular discomfort within 30 minutes of topical application and within 14 days of oral consumption.
In Paris, Dr. Hesslink presented research from radio tracer label data and ligand binding assays supporting the hypothesis that Celadrin(R) interacts with membrane receptors involved with the inflammatory cascade. To support this hypothesis, Dr. Hesslink presented dual-label tracer data from the laboratory of Dr. Daniel Gallaher at the University of Minnesota showing the appearance of the labeled components of Celadrin(R) in the phospholipid fractions. The greatest amount of the label was found in the phospholipid fractions of liver homogenates (e.g. microsomes) and white blood cell microsomes.
In addition, Dr. Hesslink presented in vitro and binding assay studies conducted by a world leading clinical discovery organization for the pharmaceutical and biotechnology industries. In these in vitro studies, Celadrin(R) was shown to inhibit the thromboxane synthase enzyme using prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2) as substrates. Thromboxane is a very strong facilitator of inflammation and local tissue damage through a variety of mechanisms. To further elucidate the mechanism of action on thromboxane production, receptor binding assays were carried out on the thromboxane A2 membrane receptor. Celadrin(R) was found to exert strong receptor binding inhibition using a standard radio binding assay.
"The appearance of labeled Celadrin(R) within cellular membranes, especially those of the white blood cells coupled with inhibition of thromboxane production or receptor inhibition suggests that Celadrin(R) influences the prostaglandin cascade and resulting inflammation," stated Dr. Hesslink. "It is this cellular data along with our safety and clinical efficacy data which provided the International Federation of Sports Medicine (FIMS) Executive Committee the confidence to select Celadrin(R) Topical Cream as FIMS' first and only Official Pain Relieving Cream."
Commenting on the presentation, Mr. William Spencer, Imagenetix's Chief Executive Officer said, "We have completed a number of clinical studies which have demonstrated the effectiveness of Celadrin(R) in both capsule and topical delivery methods. These additional studies were conducted to determine how these results are achieved. We are pleased at the reaction of scientists to this presentation and with the acceptance of Celadrin(R) within the international community. Our international distribution partners are experiencing increased sales as their consumers see the benefits of Celadrin(R). Dr. Hesslink and his team have put together an impressive portfolio of research documenting the safety and efficacy of Celadrin(R)."
Based in San Diego, California, Imagenetix, (OTCBB: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(R)-Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information on Celadrin(R), please visit, http://www.celadrin.com.
The aim of ISANH is to advance the practical applications of antioxidants, in all related fields, with particular reference to health and nutrition, and provide recommendations to ISANH's members, health decision makers and institutions about the last antioxidant trends, uses and problems. In addition, ISANH encourages communication and interaction among researchers, physicians, nutritionists, industrials, food technology and strategic marketing managers through a global antioxidants network, please visit http://www.isanh.com.
The Federation Internationale de Medecine du Sports (FIMS)/International Federation of Sports Medicine is an international organization comprised of individual members, national associations, and multinational groups, with a common involvement with sports medicine on all continents. FIMS aims primarily to promote the study and development of sports medicine throughout the world, to assist athletes in achieving optimal performance, and to enhance health through the practice of exercise and physical activity in the general population. http://www.fims.org.
|SOURCE Imagenetix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved